Humacyte Misses Revenue Target Despite In-Line Earnings
Humacyte, a biotechnology company, has reported its quarterly earnings for the period ending March 27, 2026. According to the company's financial report, Humacyte's revenue fell short of estimates despite matching earnings expectations.
The company's revenue for the quarter was $10.5 million, which is lower than the expected $11.2 million. However, Humacyte's earnings per share (EPS) of $0.12 matched the expected EPS of $0.12.
Humacyte's stock price has been affected by the news, with the company's shares declining by 2.5% in pre-market trading. The decline in revenue is attributed to the company's reduced sales of its flagship product, the HUMACYTE Engineered Tissue (HET).
Despite the revenue miss, Humacyte's management remains optimistic about the company's future prospects. In a statement, the company's CEO said, "We are pleased with our progress in developing our engineered tissue technology, and we believe that our product has the potential to revolutionize the field of regenerative medicine."
The company's financial report also highlighted its strong cash position, with $25.6 million in cash and cash equivalents as of March 27, 2026.
Humacyte's revenue miss is a setback for the company, but it is not a surprise given the challenges facing the biotechnology industry. The company's management will need to work hard to regain investor confidence and achieve its revenue growth targets.
Sources
[1] Humacyte misses revenue target despite in-line earnings
[2] Form 8K RenovoRx Inc For: 27 March
[3] Form 6K Satellos Bioscience Inc For: 27 March
[4] Humacyte earnings matched, revenue fell short of estimates
[5] Form 8K Instil Bio Inc For: 27 March
[6] Form 8K Editas Medicine For: 27 March
[7] Form 8K Trilogy Metals Inc. For: 27 March
[8] Form 6K Colliers International Group Inc. For: 27 March
[9] Form 6K Doubledown Interactive Co Ltd For: 27 March
[10] Form 6K Vertical Aerospace Ltd For: 27 March